Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 9/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3543108 | 0.89 | DRD2 (0.36) | TLR9SMN1; SMN2HSP90AA1HSP90AB1 | |
| SCHEMBL3543105 | 0.83 | SMN1; SMN2 (0.38) | SMN1; SMN2 | |
| SCHEMBL3668641 | 0.82 | ALDH1A1 (0.35) | SMN1; SMN2 | |
| SCHEMBL3543954 | 0.81 | RPS6KA3 (0.45) | SMN1; SMN2HSP90AA1 | |
| SCHEMBL3542695 | 0.81 | KDM4E (0.37) | SMN1; SMN2 | |
| SCHEMBL3543713 | 0.81 | RAD52 (0.38) | TLR9SMN1; SMN2MAPK1GAA | |
| SCHEMBL3543738 | 0.80 | SMN1; SMN2 (0.35) | SMN1; SMN2 | |
| SCHEMBL3548150 | 0.80 | RPS6KA3 (0.37) | SMN1; SMN2HSP90AA1HSP90AB1 | |
| SCHEMBL1204276 | 0.79 | PRKDC (0.46) | — | |
| SCHEMBL3543190 | 0.79 | TRPC5 (0.36) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709471-B2 | Compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-20080009482-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009482-A1 | NOVEL COMPOUNDS | CYP11B2, CYP11B1, CYP46A1 | TLR9 4628/4885SMN1; SMN2 1059/4885MAPK1 2324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.